Silva Markovic-Plese

Silva Markovic-Plese

Auto-generated profile, based on publicly available information

Silva Markovic-Plese

Department of Neurology, Thomas Jefferson University

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MSMaryamsadat Seyedsadr
Maryamsadat Seyedsadr
YWYan Wang
Yan Wang
MEManal Ali Elzoheiry
Manal Ali Elzoheiry
SGSowmya Shree Gopal
Sowmya Shree Gopal
SJSoohwa Jang
Soohwa Jang
SMSilva Markovic-Plese
Silva Markovic-Plese
The objective of this study is to examine IL-11-induced mechanisms of inflammatory cell migration to the central nervous system (CNS). We report that IL-11 is produced at highest frequency by myeloid cells among the peripheral blood mononuclear cell (PBMC) subsets. Patients with relapsing–remitting multiple sclerosis (RRMS) have an increased frequency of IL-11 + monocytes, IL-11 + and IL-11R + CD4 + lymphocytes, and IL-11R + neutrophils in comparison to matched healthy controls. IL-11 + and granulocyte-macrophage colony-stimulating factor (GM-CSF) + monocytes, CD4 + lymphocytes, and neutrophils accumulate in the cerebrospinal fluid (CSF). The effect of IL-11 in-vitro stimulation, examined using single-cell RNA sequencing, revealed the highest number of differentially expressed genes in classical monocytes, including up-regulated NFKB1, NLRP3, and IL1B . All CD4 + cell subsets had increased expression of S100A8/9 alarmin genes involved in NLRP3 inflammasome activation. In IL-11R + -sorted cells from the CSF, classical and intermediate monocytes significantly up-regulated the expression of multiple NLRP3 inflammasome–related genes, including complement, IL18 , and migratory genes ( VEGFA/B ) in comparison to blood-derived cells. Therapeutic targeting of this pathway with αIL-11 mAb in mice with RR experimental autoimmune encephalomyelitis (EAE) decreased clinical scores, CNS inflammatory infiltrates, and demyelination. αIL-11 mAb treatment decreased the numbers of NFκBp65 + , NLRP3 + , and IL-1β + monocytes in the CNS of mice with EAE. The results suggest that IL-11/IL-11R signaling in monocytes represents a therapeutic target in RRMS.

1 September 2019 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
XZXin Zhang
Xin Zhang
NKNazanin Kiapour
Nazanin Kiapour
SKSahil Kapoor
Sahil Kapoor
TKTabish H Khan
Tabish H Khan
MTMadhan Thamilarasan
Madhan Thamilarasan
SMSilva Markovic-Plese
Silva Markovic-Plese
IL-11+CD4+ cells accumulate in the cerebrospinal fluid of patients with early relapsing-remitting multiple sclerosis (MS) and in active brain MS lesions. Mouse studies have confirmed a causal role of IL-11 in the exacerbation of relapsing-remitting experimental autoimmune encephalomyelitis (RREAE). Administration of IL-11 at the time of clinical onset of RREAE induced an acute exacerbation and increased clinical scores, which persisted during the entire course of the disease. IL-11 increased the numbers of spinal cord inflammatory foci, as well as the numbers of peripheral and CNS-infiltrating IL-17+CD4+ cells and IL-17A serum levels. Ag recall assays revealed that IL-11 induces IL-17A+, GM-CSF+, and IL-21+CD4+ myelin Ag-reactive cells. Passive transfer of these encephalitogenic CD4+ T cells induced severe RREAE with IL-17A+CCR6+ CD4+ and B cell accumulation within the CNS. Furthermore, passive transfer of nonmanipulated CNS-derived mononuclear cells from mice with RREAE after a single dose of IL-11 induced severe RREAE with increased accumulation of IL-17A+ and CCR6+ CD4+ cells within the CNS. These results suggest that IL-11 might serve as a biomarker of early autoimmune response and a selective therapeutic target for patients with early relapsing-remitting MS. Key Points IL-11+CD4+ cells accumulate in the CSF and active brain RRMS lesions. IL-11 increased the numbers of CNS-infiltrating IL-17+CD4+ cells in RREAE. Passive transfer of IL-11–induced encephalitogenic CD4+ T cells induced severe RREAE.

1 April 2015 in Clinical Immunology
Verified
Journal Article
Closed access
KBKevin Blauth
Kevin Blauth
XZXin Zhang
Xin Zhang
MCManisha Chopra
Manisha Chopra
SRSarah Rogan
Sarah Rogan
SMSilva Markovic-Plese
Silva Markovic-Plese

11 January 2024 in Neurology and Therapy
Verified
Journal Article
Open access
PDF file
MFMark S. Freedman
Mark S. Freedman
PCPatricia Coyle
Patricia Coyle
KHKerstin Hellwig
Kerstin Hellwig
BSBarry Singer
Barry Singer
DWDaniel Wynn
Daniel Wynn
ARAnthony t Reder
Anthony t Reder
Multiple sclerosis (MS) is a chronic, progressive, inflammatory disorder of the central nervous system. Relapsing–remitting MS (RRMS), the most common form of the disease, is characterized by transient neurological dysfunction with concurrent accumulation of disability. Over the past three decades, disease-modifying therapies (DMTs) capable of reducing the frequency of relapses and slowing disability worsening have been studied and approved for use in patients with RRMS. The first DMTs were interferon-betas (IFN-βs), which were approved in the 1990s. Among them was IFN-β-1a for subcutaneous (sc) injection (Rebif®), which was approved for the treatment of MS in Europe and Canada in 1998 and in the USA in 2002. Twenty years of clinical data and experience have supported the efficacy and safety of IFN-β-1a sc in the treatment of RRMS, including pivotal trials, real-world data, and extension studies lasting up to 15 years past initial treatment. Today, IFN-β-1a sc remains an important therapeutic option in clinical use, especially around pregnancy planning and lactation, and may also be considered for aging patients, in which MS activity declines and long-term immunosuppression associated with some alternative therapies is a concern. In addition, IFN-β-1a sc is used as a comparator in many clinical studies and provides a framework for research into the mechanisms by which MS begins and progresses.

24 June 2022 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
NKNazanin Kiapour
Nazanin Kiapour
BWBing Wu
Bing Wu
YWYan Wang
Yan Wang
MSMaryamsadat Seyedsadr
Maryamsadat Seyedsadr
SKSahil Kapoor
Sahil Kapoor
SMSilva Markovic-Plese
Silva Markovic-Plese
The objective of this study is to determine the mechanism of action of anti-CD52 mAb treatment in patients with relapsing-remitting multiple sclerosis (RRMS). Experimental autoimmune encephalomyelitis (EAE), an animal model of the disease, was used to address the role of T regulatory cells (Tregs) in the anti-CD52 mAb–induced suppression of the disease. In vitro studies on PBMCs from RRMS patients and matched healthy controls determined the effect of IL-7 on the expansion of CD4+CD25+CD127− Tregs and induction of their suppressive phenotype. This study using EAE animal models of MS has shown that mouse anti-CD52 mAb suppression of clinical disease was augmented by coadministration of IL-7 and partially reversed by anti-IL-7 mAb. In vitro human studies showed that IL-7 induced expansion of CD4+CD25+CD127− Tregs and increased their FOXP3, GITIR, CD46, CTLA-4, granzyme B, and perforin expression. Anti-CD52 mAb treatment of mice with relapsing-remitting EAE induced expansion of Foxp3+CD4+ Tregs and the suppression of IL-17A+CD4+ and IFN-γ+CD4+ cells in peripheral immune organs and CNS infiltrates. The effect was detected immediately after the treatment and maintained over long-term follow-up. Foxp3+CD4+ Treg-mediated suppression of IL-17A+CD4+ and IFN-γ+CD4+ cells in the spinal cord infiltrates was reversed after inducible Foxp3 depletion. Our results demonstrated that the therapeutic effect of U.S. Food and Drug Administration–approved anti-CD52 mAb is dependent on the presence of Tregs.

28 August 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
MEManal Elzoheiry
Manal Elzoheiry
MSMaryam Seyedsadr
Maryam Seyedsadr
JWJohn Wrobel
John Wrobel
YWYan Wang
Yan Wang
SGSowmya Shree Gopal
Sowmya Shree Gopal
SMSilva Markovic-Plese
Silva Markovic-Plese
T Regulatory T cells (Tregs) from patients with relapsing-remitting multiple sclerosis (RRMS) exhibit impaired suppressive function, yet the underlying molecular mechanisms remain elusive. Single-cell RNA sequencing (scRNAseq) of ex vivo- sorted Tregs from RRMS patients and matched healthy controls (HCs) revealed down-regulation of type I IFN (IFN) and IL-27 signaling pathways in RRMS Tregs. These Tregs showed reduced expression of IFN-stimulated genes (ISGs) ( ISG15, MX1, IFITM1, IFI44L, OAS1 ), as well as key mediators of Treg suppressive function ( LGALS3, CD81, FCRL3, CD7, CSTB ), all suggesting a key role of decreased IFN signaling in RRMS Treg dysfunction. To therapeutically target IFN signaling pathways and improve Treg suppressive functions, we used cGAMP-loaded microparticles (MPs) to activate the stimulator of IFN genes (STING) in experimental autoimmune encephalomyelitis (EAE). cGAMP-MP treatment ameliorated EAE via induction of Tregs expressing IL-27R, IL-10, TGF-b, and Granzyme B. This effect was abolished in Treg-specific IL-27R (Treg ΔIl27ra ) knockout mice, confirming that IL-27 signaling is essential for Treg suppression. In vitro IL-27 stimulation of RRMS-derived Tregs restored expression of IFN pathway genes ( IRF1, IFNGR, IFI16 ) and Treg suppressive genes ( ICOS, IKZF3, IL7R, TIGIT ). Thus, we propose that IL-27 pre-stimulation may restore their suppressive function and migration (via CCR6, CCR7, S100A11 and S1PR4 ) to the central nervous system (CNS) in future clinical trials. Significance: Several studies have reported a role for type I IFN and IL-27 signaling in the induction of suppressive Tregs in autoimmune diseases. We report that RRMS Tregs have decreased expression of type I IFN and IL-27 signalling-related genes in comparison to HCs. The animal model of MS (EAE) was successfully treated with cGAMP-MPs, which, via induction of type I IFN, IL-27 and IL-10, restored Treg suppressive function. A scRNAseq study of Tregs from MS patients revealed that IL-27 in vitro stimulation normalized the expression of type I IFN genes and Treg suppressive genes. We propose that IL-27 pre-treatment may enhance Treg suppressive function and migration to the CNS in future clinical trials.